arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

LeonaBio, Inc.

LONA
$7.77 ▼ -0.22 (-2.75%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
29 Visible periods
19 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, LeonaBio, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $147.8M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -27.6%
FCF / Share $-1.10
Trailing P/E
Price / Book 1.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

29-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-32.95M
↓ -260.4%
FCF / Share Free cash flow per share
$-1.10
↑ +70.8%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -290.7% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.43x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 29 quarters